已收盘 09-25 16:00:00 美东时间
-0.040
-1.07%
今日重点评级关注:摩根大通:维持Ultragenyx Pharmaceutical"超配"评级,目标价从75美元升至80美元;瑞杰金融:维持英伟达"强力买入"评级,目标价从330美元升至352美元
08-26 08:37
Deutsche Bank analyst Kunal Madhukar maintains Vivid Seats (NASDAQ:SEAT) with a Hold and raises the price target from $7 to $7.5.
08-26 01:36
今日重点评级关注:HC Wainwright & Co.:维持Precigen"买入"评级,目标价从14美元升至18美元;HC Wainwright & Co.:维持Sophia Genetics"买入"评级,目标价从12美元升至14美元
08-06 11:36
RBC Capital analyst Brad Erickson maintains Vivid Seats (NASDAQ:SEAT) with a Sector Perform and raises the price target from $8 to $9.
08-06 01:24
Vivid Seats (NASDAQ:SEAT) reported quarterly sales of $129.861 million which beat the analyst consensus estimate of $122.558 million by 5.96 percent. This is a 9.55 percent decrease over sales of $143.566 million the same period last year.
08-04 18:33
今日重点评级关注:Ascendiant Capital:维持NextTrip"买入"评级,目标价从7美元升至7.5美元;Maxim Group:维持Zevra Therapeutics"买入"评级,目标价从25美元升至35美元
06-11 09:55
Morgan Stanley analyst Cameron Mansson-Perrone maintains Vivid Seats (NASDAQ:SEAT) with a Equal-Weight and raises the price target from $7.75 to $9.25.
06-11 01:59
On Tuesday, Vivid Seats (NASDAQ:SEAT) discussed first-quarter financial results...
05-05 21:34
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
Vivid Seats (NASDAQ:SEAT) reported quarterly losses of $(1.35) per share which missed the analyst consensus estimate of $(1.11) by 21.62 percent. This is a 35 percent decrease over losses of $(1.00) per share from the
05-05 18:45